EUVIMEDEUVIMED entdecken
Crossref

Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy

Guidong Li, Hiroyuki Kawashima, Taro Sasaki, Takashi Ariizumi, Naoki Oike, Akira Ogose

Anticancer Research · 2025

DOI: 10.21873/anticanres.17648 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Guidong Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The First Affiliated Hospital of Harbin Medical University, Harbin, P.R. China azumatakafumi@163.com. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Methotrexate, Osteosarcoma, Bone Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-metMethotrexateOsteosarcomaBone NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansDrug SynergismCell Line, TumorHepatocyte Growth FactorSignal TransductionCell ProliferationApoptosisDrug Resistance, NeoplasmIndolesSulfones

Stichwörter der Autor:innen

Osteosarcomaapoptosis combination therapyc-Met inhibitorsmethotrexatesignaling pathwayssynergy

Substanzen

Proto-Oncogene Proteins c-metMethotrexateHepatocyte Growth FactorMET protein, human5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl…HGF protein, humanIndolesSulfones

Autor:innen und Institutionen

  • Department of Orthopedics, The First Affiliated Hospital of Harbin Medical University, Harbin, P.R. China azumatakafumi@163.com.
  • Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
  • Department of Orthopedics, Uonuma Kikan Hospital, Niigata, Japan.

Zitieren

APA

Li, G., Kawashima, H., Sasaki, T., Ariizumi, T., Oike, N., & Ogose, A. (2025). Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy. Anticancer Research. https://doi.org/10.21873/anticanres.17648

Vancouver

Li G, Kawashima H, Sasaki T, Ariizumi T, Oike N, Ogose A. Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy. Anticancer Research. 2025. doi:10.21873/anticanres.17648

BibTeX
@article{Li2025,
  author = {Li, Guidong and Kawashima, Hiroyuki and Sasaki, Taro and Ariizumi, Takashi and Oike, Naoki and Ogose, Akira},
  title = {Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17648}
}
Kostenlos starten →